SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is under pressure as traders debate the boards investigation into CEO Jensen Huang following reports of an affair with a woman suspected of ties to China, with some fearing national-security scrutiny or Huangs departure while others see the controversy as overblown. The community is split between continued selling and buying the dip ahead of earnings, with some also pointing to broader tech weakness.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

A disappointing Q3 reportwith a surprise loss, squeezed margins, weaker-than-expected outlook and a sequential subscriber declinehas driven a sharp selloff. Traders are split between concerns about profitability and execution and hopes that international growth, the Lilly partnership and the planned Peptides+ launch can support a recovery.

Digital Turbine, Inc. engages in mobile growth platform solutions for advertisers, publishers, carriers, and device original equipment manufacturers. It operates through the following segments: On Device Solutions and App Growth Platform. The On Device Solutions segment consists of products and services that simplify the discovery and delivery of mobile apps and content media for device end users. The App Growth Platform segment provides Advertising Solutions and Ad Monetization Solutions. The company was founded on November 6, 1998 and is headquartered in Austin, TX.

Digital Turbine Inc

Digital Turbines quarterly results triggered a sharp selloff despite revenue growth and a higher sales outlook, as gross-margin compression and unchanged profit guidance raised concerns about whether growth is translating into earnings. Traders are divided between viewing the drop as an overreaction and worrying that margin pressure and debt could weigh on the turnaround.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

A third-quarter earnings beat, stronger-than-expected Q4 guidance, and an expanded buyback authorization sparked a sharp rally that quickly faded as traders weighed managements cautious tone and slowing underlying growth. Bulls see progress toward a turnaround, while skeptics point to declining year-over-year revenue, temporary revenue tailwinds, and doubts about management; the result has been intense debate over whether the report signals recovery or a sell-the-news move.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

MARAs quarterly report has focused attention on its AI/HPC pivot: traders welcomed debt reduction, a share-repurchase authorization and an initial GPU-services contract, while noting that larger AI tenant leases remain unannounced. Reactions are split over whether the pivot can diversify the business, with skeptics emphasizing the revenue miss, Bitcoin-price exposure and execution risks.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors pending FDA decision on deramiocel is the dominant focus, with traders centering on the November 22 decision and the amended applications upper-limb-function case for Duchenne muscular dystrophy. Many are optimistic about approval and a potential short squeeze, while others stress the binary risk and FDA skepticism; the AHA award for cardiac research adds to bullish sentiment but does not resolve the regulatory uncertainty.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.09792366 USD and is down -1.80 over the last 24 hours. It is currently trading on 1894 active market(s) with $2,759,095,442.76 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRP is under pressure amid a broader crypto selloff, with traders citing Bitcoin weakness, inflation concerns and leveraged-position liquidations as factors behind the decline. The community is divided between bearish calls for further losses and dip-buying bulls pointing to oversold conditions and reported whale accumulation, while many question XRPs utility and Ripples token economics.

Pepe (PEPE) is a cryptocurrency launched in 2023and operates on the Ethereum platform. Pepe has a current supply of 413,772,350,095,630.40630647. The last known price of Pepe is 0.00000511 USD and is up 0.93 over the last 24 hours. It is currently trading on 729 active market(s) with $552,678,948.79 traded over the last 24 hours. More information can be found at https://www.pepe.vip/.

Pepe

PEPEs volatile rebounds and repeated tests of a key round-number resistance are drawing attention, with traders often pointing to relative strength when the broader crypto market weakens. Bulls see the bounces as signs of accumulation or a renewed meme-coin run, while skeptics warn the rallies may fade and emphasize the sharp pullbacks.

Ethereum (ETH) is a cryptocurrency . Ethereum has a current supply of 122,203,846.69715353. The last known price of Ethereum is 2,121.02700944 USD and is down -0.91 over the last 24 hours. It is currently trading on 14303 active market(s) with $13,174,532,202.61 traded over the last 24 hours. More information can be found at https://www.ethereum.org/.

Ethereum

Ethereum is drawing attention amid a broad crypto selloff, with traders pointing to hot inflation data, increased Fed rate-hike bets, and leveraged long liquidations as sources of pressure. The discussion is largely bearish, with calls for further losses and concern about support, while some traders are buying the dip and looking for a reversal.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs sharp rally is being discussed as a potential beneficiary of Nvidia CEO Jensen Huang-related scrutiny, with traders speculating that investor money may rotate toward rivals; actual customer shifts from Nvidia remain unconfirmed. The community also points to AMDs Google Cloud EPYC deployment and analyst upgrades, while some warn the rebound is overextended and could fade.

statis crypto Watchlist

Bitcoin

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Savara Presented New Data Showing Molgramostim Inhalation Solution (Molgramostim) Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patients with Mild Diffusion Impairment

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the CHEST 2026 Annual Meeting in Phoenix, Arizona. The poster reports a post-hoc analysis of the IMPALA clinical trial evaluating the effects of...

Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026

Savara Inc. (Nasdaq: SVRA), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of an encore oral presentation on data from the Phase 3 IMPALA-2 clinical trial and a poster presentation on data from the Phase 2/3 IMPALA clinical trial at...

Notable Thursday Option Activity: SVRA, CAR, SPCX

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Savara Inc (Symbol: SVRA), where a total of 10,285 contracts have traded so far, representing approximately 1.0 million underlying shares. That amounts to about 70.6% of...

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two poster presentations on data from the Phase 3 IMPALA-2 clinical trial at the ERS Congress in Barcelona, Spain, September 5-9...

Savara Announces New Employment Inducement Grant

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. On August 17, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards to eight new...

Savara Reports Second Quarter 2026 Financial Results and Provides Business Update

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the second quarter ending June 30, 2026 and provided a business update. While we have regulatory applications under review across the U.S., EU...

Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the European Patent Office (EPO) has granted a patent covering the liquid formulation of MOLBREEVI, an orally inhaled recombinant human...

Here's Why You Should Add Savara Stock to Your Portfolio Now

SVRA advances Molbreevi with positive long-term phase III data, an FDA review on track and expanded patent protection supporting its commercial outlook.

What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline

What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline...

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. On June 11, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards to four new...

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Langhorne, PA.

Savara Inc

SVRA Stock Slips Post-Market After FDA Delays Decision On Pulmonary Therapy

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>The company was looking for FDA’s greenlight for molgramostim in Autoimmune Pulmonary Alveolar Proteinosis.</li><li>The company had submitted certain responses to the FDA recently which the agency determined represents a major amendment to the application, the company explained.</li><li>Savara added that the agency did not cite any safety, efficacy, or manufacturing concerns in their correspondence.</li></ul>Shares of Savara Inc. (SVRA) slumped as much as 4% after-hours on Wednesday after the company said that the U.S. Food and Drug Administration has extended the review time of its application seeking approval for its experimental therapy molgramostim by three months.The company was looking for the FDA’s greenlight for molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP), a rare lung disease where autoantibodies block the clearing of surfactant in the lungs, causing a buildup that disrupts oxygen exchange, creating breathing difficulties, and chronic coughing.The agency is now slated to decide on the application by November 22, Savara said. The former deadline for a decision was August 22.<h2 class="st-heading-2">Why The Delay?</h2>The company had submitted certain responses to the FDA recently, which the agency determined represents a major amendment to the application, the company explained. The additional time will allow the agency time to review the extra materials submitted, it added.Savara added that the agency did not cite any safety, efficacy, or manufacturing concerns in its correspondence.Savara completed submission of its application to the FDA for molgramostim as a treatment for aPAP in March. It was granted priority review by the agency. &nbsp;According to Savara, molgramostim has the potential to be the first and only approved therapy for Autoimmune PAP.The company had previously submitted an application for the experimental therapy but received a “refuse to file” letter from the FDA in May 2025 due to insufficient Chemistry, Manufacturing, and Controls data. The company resubmitted the application, stating that Fujifilm Biotechnologies will manufacture the drug substance. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around SVRA stock stayed within the ‘neutral’ territory over the past 24 hours, while message volume remained at ‘low’ levels.<a href="https://stocktwits.com/symbol/SVRA">SVRA stock</a> has more than doubled over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tsla-stock-on-track-for-best-day-in-nearly-seven-months-ahead-of-q1-earnings/cZJtNmERIwY">TSLA Stock On Track For Best Day In Nearly 7 Months Ahead Of Q1 Earnings As Musk Hails AI5 Milestone</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Savara Inc. (SVRA) was looking for FDA’s greenlight for molgramostim in Autoimmune Pulmonary Alveolar Proteinosis.

The agency is now slated to decide on the application by November 22, Savara said.


Vanguard Total Stock Market ETF

SPDR S&P Biotech ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$4.96
Prev Close	$5.05
Open	$4.92
Dividend Yield	0.00%
50-Day Moving Average	$4.98
Beta	1.10
Avg. Volume	2.45M
PE Ratio	-8.76

52-Week High	$7.01
52-Week Low	$4.00
Market Capitalization	$1.04B
EPS (Annual)	-$0.5344
Price to Book	7.22
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

SVRA Fundamentals